Peptides of these cancer-specific aberrant proteins are presented in complex with MHCI or MHCII on the cancer cell surface and can be recognized by appropriate CD8+ T cells and CD4+ T cells, inducing an immune response and tumor cell killing [71]. This evidence concerns the gene CD8A and cancer.